Hi All
The great thing is the latest DCF valuation of A$10-11 is only calculated on the current proven jorc amount. It also assumes a production cost of US$25/lb.
With the scoping study due out in the next couple of weeks, I can see this cost being considerably less, US$15-20/lb IMHO, given the higher grades.
I think the days that someone could mount a successful takeover offer at A$10.00 per share are now gone. I think myself a figure of around A$15.00 per share will be required for any successful takeover bid, on the current results. Mind you, I still think this would be cheap, considering the huge potential up side, the successful bidder would have acquired.
I would be happy to hold until Extract went into production to reap the rewards, but I don't think that is an option for Mr Dattels and co.
Maybe my dream won't be so far off, after all, Harlee?
Regards
Steve
- Forums
- ASX - By Stock
- EXT
- analyst upgrade dcf valuation to $10-11
EXT
excite technology services ltd
Add to My Watchlist
11.1%
!
1.0¢

analyst upgrade dcf valuation to $10-11, page-7
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.0¢ |
Change
0.001(11.1%) |
Mkt cap ! $20.72M |
Open | High | Low | Value | Volume |
0.9¢ | 1.0¢ | 0.8¢ | $31.15K | 3.390M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1600000 | 0.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.0¢ | 1109800 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1600000 | 0.009 |
6 | 1884688 | 0.008 |
6 | 5198700 | 0.007 |
4 | 2850000 | 0.006 |
2 | 1280000 | 0.005 |
Price($) | Vol. | No. |
---|---|---|
0.010 | 627812 | 2 |
0.011 | 4227645 | 5 |
0.012 | 1982124 | 5 |
0.013 | 53000 | 1 |
0.014 | 1000000 | 1 |
Last trade - 15.23pm 27/06/2025 (20 minute delay) ? |
Featured News
EXT (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online